Mr. Thomas O'Shaughnessy reports

ONCO-INNOVATIONS ADVANCES POLYMER TESTING AS IT MOVES ITS PNKP INHIBITOR TECHNOLOGY TOWARD IND-ENABLING STUDIES

Onco-Innovations Ltd. has advanced an analytical method used to measure and control a key polymer within its PNKP inhibitor technology, supporting continued formulation development and scale-up, as the company advances toward its goal of clinical manufacturing. This work is intended to help ensure consistency in the company's delivery system as it progresses toward IND-enabling studies and plans for future phase 1 clinical activities.

The analytical method, known as refractive index detection, coupled with gel permeation chromatography (RI-GPC), is used to characterize polymer molecular weight and molecular weight distribution. These measurements determine whether the polymer is being produced consistently from batch to batch. The polymer forms the nanoparticle micelle delivery system that is part of the company's PNKP inhibitor technology, and is designed to carry its lead PNKP inhibitor, ONC010, to enhance tumour-targeted delivery and persistence in circulation.

By improving analytical control over this polymer, Onco is working to strengthen formulation reproducibility, support manufacturing scale-up and reduce development risk as it prepares for later-stage regulatory and clinical work.

RI-GPC is considered a standard industry tool for evaluating polymer quality, including molecular weight distribution and polydispersity, both of which can affect how nanoparticle formulations behave in the body, how reliably they can be manufactured and how readily they can be scaled for clinical use. This analytical qualification is intended to strengthen the chemistry, manufacturing and control package for Onco's PNKP inhibitor technology and support the broader goal of preparing the program for regulatory review and clinical manufacturing.

"Establishing strong analytical control over key components of our PNKP inhibitor technology is an important part of preparing the program for the next stages of development. As we move toward IND-enabling studies and plan for future clinical execution, work like this helps support the consistency, reproducibility and manufacturing foundation that regulators and clinical programs depend on," said Thomas O'Shaughnessy, chief executive officer of Onco-Innovations.

About Onco-Innovations Ltd.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide licence to patented technology that targets solid tumours.

We seek Safe Harbor.